Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Sites / Brigham and Womens Hospital / Vitonis, Allison

Vitonis, Allison

Staff, Brigham and Womens Hospital, 617-732-7681

Contact Information

Email: mailto:avitonis@partners.org
Fax:

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Pre-operative plevic mass study 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer 0 0
Biomarker Reference Sets for Cancers in Women 0 0
PLCO Ovarian Phase III Validation Study 50 1
SPORE/EDRN/PRE-PLCO Ovarian Phase II Validation Study 55 2
Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement 28 0
EDRN Resource Network Exchange 0 0
Ovarian Cancer Screening Pilot Trial In High Risk Women 0 0

Publications

Publication Name PubMed ID Journal
Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. 11584061 J. Natl. Cancer Inst.
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. 18245537 Clin. Cancer Res.
Osteopontin as a potential diagnostic biomarker for ovarian cancer. 11926891 JAMA
Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry. 12912935 Clin. Cancer Res.
Proteomic biomarker identification for diagnosis of early relapse in ovarian cancer. 17245808 J Bioinform Comput Biol
Non-genomic biomarkers of risk in ovarian cancer. 18057519 Dis. Markers
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. 15894662 Cancer Epidemiol. Biomarkers Prev.
Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. 16428483 Clin. Cancer Res.
Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. 14581349 Clin. Cancer Res.
Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study. 19008269 BMJ
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). 19282241 Lancet Oncol.
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. 18061248 Gynecol. Oncol.
A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. 18349277 Cancer Epidemiol. Biomarkers Prev.
Urokinase-type plasminogen activator receptor: a beacon of malignancy? 18794069 Clin. Cancer Res.
Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. 15161704 Clin. Cancer Res.
Promoter hypermethylation profile of ovarian epithelial neoplasms. 16061849 Clin. Cancer Res.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.

Addresses

221 Longwood Ave.
Brigham and Women's Hospital, Dept. of OB/GYN

To update addresses, please visit the Data Management and Coordinating Center.

Announcement 06/30/2017

The next EDRN Steering Committee Meeting is from September 12-14, 2017, in Seattle WA. Please click here to register and find out more information about the meeting.

Announcement



EDRN Founder Honored

Dr. Sudhir Srivastava was honored with the Distinguished Service Award from the American Pancreatic Association at the group's annual meeting this year, for his outstanding commitment to pancreatology.